Premium
PHASE I DOSE‐ESCALATION STUDY OF VENETOCLAX PLUS BEAM FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR CHEMORESISTANT, RELAPSED/REFRACTORY, OR HIGH‐RISK NON‐HODGKIN'S LYMPHOMA (NHL); PRELIMINARY RESULTS
Author(s) -
Maakaron J.,
Zhao Q.,
Puto M.,
Von Derau R.,
Robinson J.,
Brammer J.,
Penza S.,
Baiocchi R.,
Christian B.,
Maddocks K.,
Saad A.,
Wall S.,
Benson D.,
Efebera Y.,
Rosko A.,
Ayyappan S.,
Grieselhuber N.,
Vasu S.,
Larkin K.,
Epperla N.,
Devarakonda S.,
Choe H.,
Chaudhry M.,
Blaser B.,
Blachly J.,
Bhatnagar B.,
Alinari L.,
Mims A.,
Jaglowski S.,
William B.M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.213_2631
Subject(s) - venetoclax , medicine , regimen , oncology , common terminology criteria for adverse events , autologous stem cell transplantation , melphalan , lymphoma , transplantation , adverse effect , leukemia , chronic lymphocytic leukemia